Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises funds managed by Triton in connection with acquisition
Mandate

Vinge advises funds managed by Triton in connection with acquisition

April 30, 2018 Banking and Finance

Vinge has advised funds managed by Triton in connection with the acquisition of the privately owned company Mark & Energibyggarna i Göteborg AB, a supplementary acquisition to its portfolio company Akeab.

Mark & Energibyggarna is a successful supplier of services within facility construction in the Gothenburg area. Mark & Energibyggarna is connected to KEWAB and Akeab as a new sister company in an infrastructure group, focused on facility and construction work, owned by Triton and the management of the companies in question.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Oscar Rydén, Johanna Wiberg and Michaela Cronemyr. Partner Albert Wållgren and associates Adelwald and Sara Osman provided financing advice. Partner Marcus Glader and associates Xandra Ståhlberg and Fredrika Hjelmberg provided competition law advice.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025